Nazik Hülya, Mülayim Mehmet Kamil, Öztürk Perihan
Department of Dermatology, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.
Postepy Dermatol Alergol. 2019 Dec;36(6):734-738. doi: 10.5114/ada.2019.91424. Epub 2019 Dec 30.
Omalizumab is a current treatment option for IgE-associated dermatoses, such as urticaria and atopic dermatitis.
To evaluate the clinical and laboratory findings of patients with chronic urticaria and atopic dermatitis who received omalizumab.
This study was planned as a cross-sectional and retrospective one. One hundred forty-six cases were included in the study. Omalizumab at a dose of 300 mg for patients with chronic urticaria and 600 mg for patients with atopic dermatitis, was given every 4 weeks. The response to the given treatment and remission status of patients were investigated.
Of 146 patients included in the study, 70.5% ( = 103) were female and their mean age was 42.3 ±13.8 (min.-max.: 14-85). Of the patients, 136 had chronic urticaria and 10 had atopic dermatitis. 29.9% ( = 26) of patients with chronic urticaria had a complete response to omalizumab treatment, whereas 40% ( = 4) of patients with atopic dermatitis had remission.
The decline of complaints with different treatment schemes in different patients suggests that treatment should be designed individually and that personal biomarkers playing a role in the effectiveness of the drug are important. Patients with the high IgE and eosinophil percentages and positive autologous serum test had a better treatment response to omalizumab treatment. Meanwhile, remission was found to be more frequent in atopic dermatitis patients with omalizumab treatment compared to the patients with urticaria. It may be more appropriate to choose patients based on certain criteria to ensure cost-effectiveness in omalizumab treatment.
奥马珠单抗是目前治疗IgE相关皮肤病（如荨麻疹和特应性皮炎）的一种选择。
评估接受奥马珠单抗治疗的慢性荨麻疹和特应性皮炎患者的临床和实验室检查结果。
本研究设计为横断面回顾性研究。146例患者纳入研究。慢性荨麻疹患者给予300mg奥马珠单抗，特应性皮炎患者给予600mg奥马珠单抗，每4周给药一次。调查患者对给定治疗的反应及缓解状态。
纳入研究的146例患者中，70.5%（n = 103）为女性，平均年龄为42.3±13.8岁（最小 - 最大：14 - 85岁）。其中，136例患有慢性荨麻疹，10例患有特应性皮炎。29.9%（n = 26）的慢性荨麻疹患者对奥马珠单抗治疗有完全反应，而40%（n = 4）的特应性皮炎患者缓解。
不同患者采用不同治疗方案后症状的减轻表明，治疗应个体化设计，且在药物疗效中起作用的个人生物标志物很重要。IgE和嗜酸性粒细胞百分比高且自体血清试验呈阳性的患者对奥马珠单抗治疗反应更好。同时，发现奥马珠单抗治疗的特应性皮炎患者比荨麻疹患者缓解更频繁。为确保奥马珠单抗治疗的成本效益，根据特定标准选择患者可能更合适。
